Reddit Posts
Altimmune and Viking are the last two companies left for Pharma to FOMO into the Obesity market
Altimmune and Viking are the last two companies left for Pharma to FOMO into the Obesity market
7 Diabetes and Weight Loss Drug Stocks With Big Potential
VIKING therapeutics VKTX trying to go high.. seeing unusual call activities..
VKTX yesterday there was high unusual call activities there must be something nrws, it can spike to the new high..
VKTX lot of unusual call activity(half million twice) today, there must be something, get into this guys..
Viking stock jumps on early-stage data for obesity drug (NASDAQ:VKTX)
I Told You Guys Early On We Were In For A Treat From The Healthcare Sector 📈 Only 2 Stocks With Trading Plans Posted Today In The Chatroom ✌️ $VKTX $BMEA Not 10 - 20 Stocks ❌ Both Stocks Closed Green After Hours Making New Highs ✔️ This Is Why We Have The #1 Chatroom For Breakout Alerts 🚨
I Told You Guys Early On We Were In For A Treat From The Healthcare Sector 📈 Only 2 Stocks With Trading Plans Posted Today In The Chatroom ✌️ $VKTX $BMEA Not 10 - 20 Stocks ❌ Both Stocks Closed Green After Hours Making New Highs ✔️ This Is Why We Have The #1 Chatroom For Breakout Alerts 🚨
$VKTX The Original Trade Alert Before The Trading Plan 7:08 AM 🚨 A Little Early For Most ☀️ ☕️ 3 Trading Plans In Total On This Play Alone Today , $13.88 Entry By Far The Best ✔️
$VKTX The Original Trade Alert Before The Trading Plan 7:08 AM 🚨 A Little Early For Most ☀️ ☕️ 3 Trading Plans In Total On This Play Alone Today , $13.88 Entry By Far The Best
$VKTX Started The Morning Superb 😃 After The Bell We Needed A Gap Fill 😴 Very Low Range With Each Candle 😴 The Price Action Isn’t Bad But The Range Is Very Low 😴 $BMEA $ITCI $OSCR $SPY
$VKTX Started The Morning Superb 😃 After The Bell We Needed A Gap Fill 😴 Very Low Range With Each Candle 😴 The Price Action Isn’t Bad But The Range Is Very Low 😴 $BMEA $ITCI $OSCR $SPY
VKTX$ Viking Therapeutics - Thoughts on this stocks?
VKTX$ Viking Therapeutics - Looking for thoughts/ideas
VKTX is on the rise !! 🛸🛸🛸 support this life changing company 🤔🤔
Mentions
Cash in hand: $808M Injectable Phase 3 study registrations: \~$300M Oral Phase 3 study (IF FDA says go): another \~$300M+ Do the math, boys. That "fundamentals" crap? My ass. Yeah, VKTX *could* be a 10x rocket ship… **if** you’re buying at $10. Me? Been holding over a year at way higher. Best case? I crawl out with 2x by 2028 if they either actually launch a product or get bought out. Slow-play this one, guys.
How regarded am I for just buying a bunch of: $ASTS $GLXY $VKTX $KLAR
$NVO $VKTX $UNH this week oracle move
Go all in on $VKTX . Sky or ground! Total yoloing culture
Lol I was scrolling to see more info about VKTX here, are you stalking me?
I'm following expedientcrusader and he says to day trade VKTX, thoughts on this?
ATYR biotech stock trading at ~5 per share has a major binary event coming up soon, phase 3 readout for efzofitimod. Stock will either moon to 20+ or crater to sub 1, no in between. It’s a total coinflip — up to you if you want to gamble but i’m personally sitting this one out after getting burned by VKTX phase 2 oral data
Best stock for last quarter: $NVO $UPS $TTD $VKTX wht you pick
Been in $NU calls for 06/26 20C since 0.70$. I think I got a 5x coming in the next couple weeks. Oh and $VKTX buyout any day now. Holding shares. Wish me luck!
why did shrek pay a visit to VKTX last minute?
Make VKTX a meme stock. The short interest is crazy. It would pop.
Who is gonna ape into $VKTX with me
VKTX being shorted again
yeah the discontinuation rate for the placebo group makes the trial seem like it was pretty poorly constructed. I think investors were hoping they'd be able to jump straight to phase 3 with their oral pill like their injectable but with their results they'll end up going to 2b. the bull case for VKTX IMO is still the acquisition target argument. however that's something that's been rumored for years now and is hard to predict.
VKTX (Viking Therapeutics) Viking has a new oral GLP-1 medication moving into Phase 3 trials. Importantly, GLP-1 drugs that reach Phase 3 have shown about a 60% approval rate historically. This is a long-term play, but options are already available out to Dec 2027. The company could be an acquisition target before then, and it also has other drugs in its pipeline. Shares are trading cheaply right now after an unwarranted selloff on a less-than-perfect Phase 2 readout — but the trial was still a success, and the data is promising. If approved, this would be the first low-dosage, oral GLP-1 therapy on the market. At ~$25 per share today, analysts suggest fair value could exceed $250 on approval.
My whole port is FUBO and VKTX didn’t even realize some shit was red today
VKTX feels like algos fighting each other.
I am all in on VKTX, but let’s be real about oral. You should only look at 15, 30 and 60mg efficacy. You can’t just take the efficacy of 120mg and claim it is superior to tirz. 120mg has way too many side effects and is costly to produce. What is realistic though is for 60mg to reach > 15% efficacy after a year.
Some free DD. June 2026 20C $0.70 $NU Easy money. Oh and $VKTX buyout in the next couple weeks. Shares.
Sold my tesla puts for a $20 gain and bought 200 shares of VKTX. Calls on humans being too lazy to exercise or eat healthy
Read my DD I made yesterday on VKTX- you would be up 40-60 percent today if you bought yesterday https://www.reddit.com/r/wallstreetbets/s/YbuBuOroBB
VKTX what did I tell ya
The bull case for Viking Therapeutics (VKTX) at ~$25 is that it offers best-in-class efficacy in obesity treatment with its oral and injectable GLP-1/GIP drug VK2735, which has shown double-digit weight loss in mid-stage trials, surpassing oral competitors. Tolerability concerns appear manageable with dose adjustments. Beyond obesity, Viking has multiple shots on goal with VK2809 for NASH (positive Phase 2b) and VK0214 for a rare metabolic disorder, supported by a war chest of ~$808M in cash and no debt, giving it years of funding runway. Analysts remain overwhelmingly bullish, with average targets around $87 (230%+ upside) and many reiterating Buy ratings after the selloff, and the company is frequently cited as a prime takeover candidate by large pharma players seeking an obesity franchise, which could deliver significant upside beyond standalone execution.
No, I was making money on VKTX calls. But damn I'm regretting today wasn't the day I bought GOOG calls again.
I'd say the real jewel here is subq VK2735 not oral. Oral is a nice thing to have, but most of the rev will be from subq. However what differentiates VKTX is that they would be able to do a subq into oral low dose (30-60mg) for maintenance with a low AE profile, something that isn't really replicated by anyone else (only NVO atm but oral semaglutide doesn't seem competitive at all). As I explained in previous comments (if interested you can look into my comment history), the drop was caused mainly by the weirdly high AEs in the placebo arm. When placebo-adjusted, the bear thesis falls immediately because the safety profile of even the highest dose of oral VK2735 is similar to subq tirzepatide (which is a crazy feat). I do believe the share price is artificially repressed by the institutions currently shorting. But it doesn't matter, this is a long term play and I believe it could go up a lot in the coming years. Bullish.
VKTX had disappointing results in their most recent clincal trial which is why the stock dropped 40% mid august.
Buying both $LLY and $NVO is the way (even $VKTX if you want to go nuts). There’s easily enough market of fatties globally to support multiple winners and the sentiment/price got so beaten down that there’s really just one extremely unlikely way this trade fails, and that’s trump nuking this entire industry with absurd tariffs, which it seems from the Big Beautiful Bill he has no support at all from Congress on (they’re all completely bought off by the massive pharmaceutical lobby). Plus i think they’d just jack up prices on all the other smaller market countries like Germany vs ever reduce prices more than a token amount which they’ve already done on US consumers. Worst comes to worst they’ll tie it up in the courts and block for eternity Tl;dr hang in there through the small regulatory chop the next month or so and get rich, our ADD president has no patience or follow through and will move off this bullshit and onto the next shiny object soon enough at which point these rip to the moon again
Wait for VKTX. This is worth 100 to 150 usd.
I hope you are right. I am heavily into VKTX right now. 40% of my life's savings are in there. Fingers crossed.
They are starting showing up at investor conferences starting 5 September 2025. Let's see what happens. LLY shot up because they have a proven subcutaneous version in the market. VKTX doesn't have that yet.
LLY, NVO, even VKTX after the recent reset are all going to print.
AE is adverse events. Oral VK2735 is 1.5 years behind orforglipron, that's nothing. You need to consider the fact that the TAM will increase substantially in the coming years and should reach 150-200B by 2030. It doesn't really matter if VK2735 is a few years behind orforglipron/tirzepatide considering this. The goal isn't to capture 50%+ of the market lol, or else VKTX's valuation would be a few hundred billions. Even 5% of the market would provide absolutely crazy upside relative to today's share price. This is the thesis. Considering subq VK2735 is similar/better than tirzepatide (better WL, similar safety profile) and considering oral VK2735 looks better than the competition (crazy WL compared to orforglipron and similar/better safety profile), I honestly don't think it would be unreasonable to think 20% of the market would be impossible to capture. But I prefer to tread on conservative grounds (which is still a crazy risk/reward in my opinion). Phase 3 data probably in mid 2027. Approval by mid 2028 could be possible.
Made a surgical 2% on my money on VKTX calls yet again, and I'm out. Good luck.
$VKTX weight losing stock < money losing stock 😔
Nice one. Perhaps I should have diversified into VKTX. Oh well... well played sir!
OKLO INTC SOFI and yes VKTX
Long dated VKTX calls. Oversold imo. Lotto llay
Bought VKTX that day it dropped to like 25 on a whim, not my worst play
Turns out the next play was VKTX again once it dropped. VKTX I love you. https://www.reddit.com/r/wallstreetbets/comments/1n1cv0b/daily_discussion_thread_for_august_27_2025/naylsge/?context=3
I'm not as degenerate as most of you, but I made $2000 on VKTX and immediately want to find the next play instead of enjoy a good day. (Yes, $2000 is a good day for me.)
I told you guys about LLY and VKTX...but who listens to the biotech guys
VKTX is extremely undervalued While the 28% dropout rate raised concerns, the difference from placebo (18%) isn’t huge especially considering the strong weight loss results. Compared to Lilly, this drug is showing competitive efficacy and gaining attention for its potential to grab meaningful market share. Management is confident tolerability can be improved with dose adjustments. With analysts targeting $100–$200, no way it’s gonna stay down too long
VKTX is extremely undervalued The 28% dropout rate raised concerns, but with placebo at 18%, the gap isn’t alarming, especially given the standout weight loss results and clear dose response. Management sees a clear path to improving tolerability with slower titration. Analysts say the selloff was a major overreaction, and with strong efficacy, this looks like a rare buying opportunity. Price targets are in the $100–\$200 range, this stock can’t stay down for long
So you don't have any arguments. There are shorts and there are longs. I posted my long thesis. You have no short thesis, other than you saw some people on X who are short VKTX. I did see one of those pharma guys bashing VKTX - he was comparing VKTX oral to LLY's injectable. In what world does a credible person compare oral to injectable?
PFE not making a move for VKTX is why they are such a loser. Nobody wants cobid vaccine
Arent the results worse than both NVO and VKTX?
Algos loving VKTX. Nothing organic about the price movement.
How do you feel about VKTX now? Do you think it will recover some day? Did you get out? I'm giving it a look over after the "disappointing" trial results came out.
Who is the market maker for memes and short squeeezes? Cuz we are always playing stocks someone else already ran up? We need to make VKTX fly because unlike many others, the story on this one makes sense.
Since WSB like short squeeeze so much, I don't know why y'all haven't gotten a hold of VKTX. High short interest. Just posted phase 2 results of their oral weight loss pill with weight loss % on pace to match or beat the top dogs. Market overreacted because of nausea and dropout numbers, forgetting that this was a 13 week trial with fast titration that contributed to the nausea and drop outs. Eli Lilly's pill and Novo's pill had at least 6 more months to work with, for slower titration. And VKTX almost beat them in just 13 weeks , whicwithh a high chance of surpassing them once they do phase 3 trials with a slower titration and longer trial. They are also one of the top buyout candidates.
It also came out the top with VKTX, where LLY's did not have those issues. FYI.
Wish I’d never heard the name VKTX. Fatties can’t control their bowels and it gets a 50 percent haircut.
before anyone asks why i kept the price > $5, that was by request from you guys. got into VKTX after the -40% dump and i’m holding. also took a bull call spread since i think $30 is very doable into next months. grabbed KYMR last month, avg $36. the rest are PDUFAs lined up for september/october, not this month. have fun out there and trade/invest safe. nfa, and do your own research (double and triple-check it all....everything)
BULL and VKTX both gapped up at the same time on absolutely no news. Huh.
haha i actually like VKTX, but have never owned it
Your post history makes me want to cry. Are you still holding VKTX?
My autistic lizard brain just informed me that VKTX will shoot back up to 45 bucks today.
Apparently VKTX achieves 12% weight loss in 13 weeks, and Eli Lilly 12.4% in 72 weeks.... is some nausea tolerable? If so, seems like VKTX is by far the better choice...
Spreading $10k on lotto leaps for $TTD, $VKTX, $UUUU
VKTX leaps are free money
Why? What makes VKTX so appealing? Looking at its past year growth graphs the stock has been plummeting
Dumbing down the Phase 2 study results. Out of a total of 280 people, there were 240 VK2735 participants and 40 placebo participants (this is important, and could explain skewed placebo results) **Dropout Rates & Safety/Tolerability** * **Overall discontinuation:** * VK2735 group: 28 % * Placebo: 18 % * **Discontinuation due to adverse events:** * VK2735: 20 % * Placebo: 13 % * **GI-related side effects:** * **Nausea: VK2735: 58 % vs Placebo: 48 %** * Vomiting: VK2735: 26 % vs Placebo: 10 % The high numbers of discontinuations and even higher number of GI related side effects spooked some BIG investors - the volumes traded were off the charts. However, placebo data was markedly. If its legitimate, it means VKTX is very very promising! On the other hand, If they faked it soften the blow, it means VKTX oral is not going to capture significant market share and may not even get FDA approvals. It will then compete primarily in injectables. The 48% placebo data is the one **SCREWY** number in the press release. Because VK2735 GI side effects can be improved in future via dosing and titration but what the heck you gonna do for placebos lol Waiting to see if any analysts revise their outlook upward or lower after this report. I'm in for 40K in at 31.5 USD. Not too worried but I will cut down to 10K if analysts revise their forecasts downwards. **Important question - who sold on August 19th 2025? Most of us small retail investors didn't. Here's my take.** 1. Hedge funds used HFT algos to buy the headline sell the (fine-print) news - huge momentum using heavily leveraged option bets. They first created a short-squeeze to drive up price pre-market and then created MASSIVE fresh shorts to push down the stock - 80% 2. Institutions definitely rebalanced and sold equity shares - most haven't reported yet (except Vanguard and Citadel) - I estimate this at 16-18% - waiting for data 3. Retail investors who panicked - 2-4 %
Yes - VKTX is trading on the long term average VWAP, experiments aside, the outlook remains positive.
I’ve got a small position of VKTX and added more this week. You still optimistic?
Based on my port, VKTX - picked up some shares at the bottom on the thesis that it should revert to the mean and then keep running on the basis of the magnitude of the rise.
I hate VKTX...but I love it at the same time
Let's get a nice VKTX pump to 30 real quick
I mean...I thought VKTX would bounce at least *a little bit*...
the discontinue rate being high is why VKTX sold off NVO has a high discontinue rate versus LLY
Novo is more or less a speculative play. The massive run up last year was driven by Ozempic + hype. Basically first to market with GLP-1's. Competitors appeared & the market is now kinda flooded with those and everyone panicked... share price faceplanted. It's getting attacked from all sides from compounders (more or less blatantly stealing IP), to competitors like lilly & VKTX introducing their own solutions. Novo is showing very promising results with their oral GLP-1's. They're going to very likely be first to market... estimates by as much as ~9 months. Viking therapeutics (VKTX) had some pretty poor results - leading only 2 real players left. Novo & Lilly. Novo's results are looking better than Lillys & they are further along in their pipeline which suggests to me that Novo will be first to market for an oral GLP-1. That should (hopefully) drive hype / attract attention to novo & secure a good market position. Doctors tend to prescribe things that they are familiar with & the value of being first to market is HUGE. The size of this market is estimated to be > $150b within a decade (up from $15b today). Patients would much rather pop a pill once a day than have to inject themselves with needles. Like - significantly so. Talk to people about their preferences and 9/10 would take the convenience of a pill over a needle - even if the needle may work slightly better. As long as the results are *good* (everything is looking ok based on their clinical trials) they'll establish themselves as a market leader & be first to market here. Big-ish bet around that. It's hard to say about the market itself tho... there are threats that the next generation work significantly better. That's a while away tho & hoping NVO recovers by then. From a financial perspective - they'll be fine. They are a massive company & just got a new CEO. It seems he was put in place with an understanding that 'we need to care about the share price'. --- For UNH - It's a bet that basically the US healthcare system isn't going anywhere. I don't have a ton to say on this. My bet already hit & I'm free rolling at this point (I took out ~500k of profits and left myself with a $600k bet on it). I doubt UNH is going anywhere... it makes over a billion a day in revenue. They'll not go down easy - they'll come up with new plans, adjust premiums, etc to retain their profit margins. I currently hold 400c's but it's beyond my price targets (they're similar to yours for me exiting). I'm utilizing them to obtain leverage & understand how to greeks impact the price of the options.
hey, VKTX...you know that you can go up right?
My plays for the day, lemme know what you guys think: CHYM, OKLO, VKTX, ACHR, CAPR, CRWV, FIG. To the moon we go
Someone just dumped their VKTX bags
If you sold puts on VKTX two days ago, you would've been completely up shits creek lol
VKTX calls were the easiest $ ever. Rolling into shares to sell OTM calls for easy premium, could care less about owning the stock. Open interest on Jan ‘26 calls is insane.
Interesting. Maybe regeneron is stupid? If you are right, perhaps someone snaps up VKTX soon, buying on the dip. Doesnt seem like that's Pharma's game tho.
VKTX looking good even with all the shorts against it.
Vktx has $800 million cash, valued at $2.6 billion. Meaning the asset worth 1.8 billion altogether. Regeneron bought the US right of an GLP1/GIP injectable from China for $1.9 billion. And Regeneron has to swallow the cost and time of doing the US P2/3 trials. So VKTX's injectable, which in P3, is worth 1.9 Billion at least, let alone it is better and a couple of years ahead of the Chinese one. By the calculation, the value of VKTX oral formula has zero value. And their MASH product sitting for P3, zero.
NVO has dropped a lot this year. It has reached the bottom. It’s quite cheap considering it’s a growth company with double digit growth at this size. I bought some calls expiring next year. The competition is intense for GLP-1. The current incumbents such as NVO and LLY will win eventually as they have drugs in the market already. Late comers like VKTX will struggle to keep up. See the drop of VKTX yesterday.
This is my last warning message: if you have not bought VKTX 30$ calls, make sure to tell your kids that you are the reason they have to eat boots with ketchup for dinner
VKTX wants to gap back up so bad
VKTX pumping lmfao